Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss		Retained Earnings	Treasury Stock	Noncontrolling Interests in Subsidiaries
Beginning balance (in shares) at Dec. 31, 2023			32,488
Beginning balance at Dec. 31, 2023		$ (443,616)	$ 492	$ 452,290	$ (7,803)	[1]	$ 219,027	$ (1,123,098)	$ 15,476
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[2]	14,815					14,636		179
Other comprehensive income (loss), net of tax		249			249	[1]
Dividends on common stock		(15,023)		32			(15,055)
Exercise of stock options (in shares)			18
Exercise of stock options		841	$ 1	840
Acquisition of Company common stock		0
Stock-based compensation expense		(370)		(370)
Issuance of restricted stock (in shares)			141
Issuance of restricted stock		0		(4,710)				4,710
Tax effect of restricted stock awards (in shares)			(45)
Tax effect of restricted stock awards		(3,192)		(3,192)
Distributions to noncontrolling interests		(222)							(222)
Other (in shares)			2
Other		95		(97)				192
Ending balance (in shares) at Mar. 31, 2024			32,604
Ending balance at Mar. 31, 2024		$ (446,423)	$ 493	444,793	(7,554)	[1]	218,608	(1,118,196)	15,433
Beginning balance (in shares) at Dec. 29, 2024		32,600	32,646
Beginning balance at Dec. 29, 2024		$ (414,216)	$ 493	452,449	(8,456)	[3]	241,717	(1,115,729)	15,310
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[4]	9,313					9,222		91
Other comprehensive income (loss), net of tax		916			916	[3]
Dividends on common stock		(15,116)		29			(15,145)
Exercise of stock options		0
Stock-based compensation expense		3,669		3,669
Issuance of restricted stock (in shares)			103
Issuance of restricted stock		0		(5,215)				5,215
Tax effect of restricted stock awards (in shares)			(24)
Tax effect of restricted stock awards		(1,120)		(1,120)
Distributions to noncontrolling interests		(276)							(276)
Other (in shares)			3
Other		$ 21		(187)				208
Ending balance (in shares) at Mar. 30, 2025		32,700	32,728
Ending balance at Mar. 30, 2025		$ (416,809)	$ 493	$ 449,625	$ (7,540)	[3]	$ 235,794	$ (1,110,306)	$ 15,125

[1] At March 31, 2024, the accumulated other comprehensive loss of $7,554 was comprised of net unrealized foreign currency translation loss of $7,912 and net unrealized gain on the interest rate swap agreements of $358.

[2] Net income to the Company for the three months ended March 31, 2024 excludes $99 allocable to the redeemable noncontrolling interests for our joint venture arrangements.

[3] At March 30, 2025, the accumulated other comprehensive loss of $7,540 was comprised of net unrealized foreign currency translation loss of $7,486 and net unrealized loss on the interest rate swap agreements of $54.

[4] Net income to the Company for the three months ended March 30, 2025 excludes $30 allocable to the redeemable noncontrolling interests for our joint venture arrangements.